French pharma giant Sanofi (Euronext: SAN) has secured European Union approval for Sarclisa (isatuximab) for certain people with newly diagnosed multiple myeloma.
The nod covers treatment with the antibody, in combination with VRd, for people who are ineligible for autologous stem cell transplant.
The approval, based on findings from the Phase III IMROZ study, positions Sarclisa as the first anti-CD38 plus VRd combo for this patient population in the EU, giving Sanofi a boost in its competition with Johnson & Johnson’s (NYSE: JNJ) Darzalex (daratumumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze